1 Jewish General Hospital and Lady Davis Institute for Medical Research, 3755 Chemin de la Cote St. Cathérine, Montreal, Québec, H3T 1E2, Canada. alexander.thiel@mcgill.ca.
2 Department of Neurology & Neurosurgery, McGill Univesrity, Montreal, Canada. alexander.thiel@mcgill.ca.
3 Department of Neurology & Neurosurgery, McGill Univesrity, Montreal, Canada.
4 Brain Imaging Center, Montreal Neurological Institute, Montreal, Canada.
5 Department of Chemistry, McGill University, Montreal, Canada.
6 Jewish General Hospital and Lady Davis Institute for Medical Research, 3755 Chemin de la Cote St. Cathérine, Montreal, Québec, H3T 1E2, Canada.
7 Medical Physics Unit, McGill University, Montreal, Canada.
8 PERFORM Centre Concordia University, Montreal, Canada.
9 Cross Cancer Institute, Medical Isotope Cyclotron Facility, University of Alberta, Edmonton, Canada.
10 Biomedical Chemistry, Clinic of Radiology and Nuclear Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
11 Molecular Imaging and Radiochemistry, Clinic of Radiology and Nuclear Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
12 Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Canada.
13 Department of Oncology, Division of Oncologic Imaging, University of Alberta, Edmonton, Canada.
14 Medical Faculty, University Bern, Bern, Switzerland.

Background: Reduced expression or impaired signalling of tropomyosin receptor kinases (Trk receptors) are found in a vast spectrum of CNS disorders. [¹⁸F]TRACK is the first PET radioligand for TrkB/C with proven in vivo brain penetration and on-target specific signal. Here we report dosimetry data for [¹⁸F]TRACK in healthy humans. 6 healthy participants (age 22-61 y, 3 female) were scanned on a General Electric Discovery PET/CT 690 scanner. [¹⁸F]TRACK was synthesized with high molar activities (A_m = 250 ± 75 GBq/µmol), and a dynamic series of 12 whole-body scans were acquired after injection of 129 to 147 MBq of the tracer. Images were reconstructed with standard corrections using the manufacturer's OSEM algorithm. Tracer concentration time-activity curves (TACs) were obtained using CT-derived volumes-of-interest. Organ-specific doses and the total effective dose were estimated using the Committee on Medical Internal Radiation Dose equation for adults and tabulated Source tissue values (S values).

Results: Average organ absorbed dose was highest for liver and gall bladder with 6.1E-2 (± 1.06E-2) mGy/MBq and 4.6 (± 1.18E-2) mGy/MBq, respectively. Total detriment weighted effective dose E_DW was 1.63E-2 ± 1.68E-3 mSv/MBq. Organ-specific TACs indicated predominantly hepatic tracer elimination.

Conclusion: Total and organ-specific effective doses for [¹⁸F]TRACK are low and the dosimetry profile is similar to other ¹⁸F-labelled radio tracers currently used in clinical settings.